Using surrogate failure time data to increase cost effectiveness in clinical trials

DOI10.1093/BIOMET/80.4.823MaRDI QIDQ4299462zbMATH OpenOpenAlexFDO

Authors Michael R. Kosorok, Thomas Fleming

Publication date 4 July 1994

Published in Biometrika (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1093/biomet/80.4.823

zbMATH Keywords

asymptotic joint distributioncensored datafailure timeslinear rank statisticmartingalemultiple endpointssurrogate outcomeweighted log rank

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Recommendations

• Analyzing survival data in conjunction with time-dependent surrogate endpoints in clinical trials
• Validation of Surrogate end Points in Multiple Randomized Clinical Trials with Failure Time end Points
• Using a surrogate marker for early testing of a treatment effect
• An information-theoretic approach to surrogate-marker evaluation with failure time endpoints
• The Evaluation of Multiple Surrogate Endpoints

Cited in

(7)

• Improving efficiency in clinical trials using auxiliary information: Application of a multi‐state cure model
• Robust Covariate‐Adjusted Log‐Rank Statistics and Corresponding Sample Size Formula for Recurrent Events Data
• Investigation of disease-free survival as a surrogate endpoint for survival in cancer clinical trials
• Analyzing survival data in conjunction with time-dependent surrogate endpoints in clinical trials
• Properties of A Nonparametric Test for Early Comparison of Treatments in Clinical Trials in the Presence of Surrogate Endpoints
• Using categorical markers as auxiliary variables in log-rank tests and hazard ratio estimation
• Some comments on efficiency gains from auxiliary information for right-censored data

This page was built for publication: Using surrogate failure time data to increase cost effectiveness in clinical trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q4299462)